trial

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

NCTId NCT00616798
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 323 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2010-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
323 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-03
Primary completion
2010-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
RO4917838Standard Antipsychotic Therapy

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients Wit — primary completion2010-02

Facts & assertions

4 sourced
Enrollment
323
Phase
PHASE2
Primary Completion Date
2010-02
Status
COMPLETED
relationships
The graph out of here
drug
RO4917838
drug
Standard Antipsychotic Therapy
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication